• Lonnie Granier

NIDA Directors on the Importance of Patient Preference in Opioid Medication Development

Dr. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), and Dr. Wilson Compton, Deputy Director of NIDA, recently published a commentary regarding a new study on extended-release injections of buprenorphine. The commentary by NIDA states that patient voices and preferences have often been left out of medication development efforts and that patient preferences and outcomes may serve as an important metric in medication trials. In addition, they NIDA notes that extended-release formulations may have benefits in settings where patients have difficulty accessing consistent care such as justice settings, populations experiencing homelessness, and in rural communities. Read more

2 views0 comments

Recent Posts

See All

Advancing Racial Justice in Addiction Medicine

Policy Statement from the American Society of Addiction Medicine (ASAM) Addiction involves complex interactions among an individual’s brain circuits, genetics, the environment, and their life experien